Camelid TB Serology Quarterly Report: 1st July to 30th September 2015
Source: environment.data.gov.uk (2024-10-03)

Camelid TB Serology Quarterly Report. Camelid TB Serology Quarterly Report.

Camelid TB Serology
Quarterly Report
Number: 2
Report Period 1st July to 30th September 2015
Issued 07 October 2015

Submission Reason
Explanation
APHA /DEFRA
At Government expense
Parallel Test:
PAR-TB
TB breakdown herd with confirmed M. bovis infection (including Wales where Officially
TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)
PAR-SUS
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions
PAR-TRC
Forward  tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in
Wales only co-located on the same premises with infected cattle, sheep, deer, goats
& pigs)
Serial Test:
SER-CONT
Herd not under restriction but contiguous to a TB-infected herd
SER-COL
Herd not under restriction but co-located with an infected herd of cattle, deer, goats
etc. (Eng & Scot only)
SER-EPI
Herd not under restriction but TB tested due to an epidemiological link with a known
infected herd (e.g. back-tracing)
Commercial/Private
At Owner expense
SER-MVT
Pre- or post-movement test
SER-EXP 
Pre-export test
SER-DIAG
Diagnostic to exclude TB from a differential diagnoses in a herd not restricted (TB
strongly suspected)
SER-RHT
Monitoring - voluntary routine testing (herd nor restricted)
Quarterly Camelid Serology Report
Test Criteria
The camelid TB serology (antibody) test comprises two separate antibody tests in a test package that can be applied
flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test interpretation
respectively. The sensitivity and specificity values of combined antibody testing for camelids were described under AHVLA
Project FT1477 as follows (see also Rhodes et al., 2012);
Sensitivity = 81.3% [71.9-91.6]    [95% confidence intervals]
Specificity = 95.8% [93.3-98.2]
Parallel Test (e.g. confirmed breakdown herd test – for increased sensitivity):
Serial Test (e.g. movement test – for increased specificity):
Sensitivity = 55.8% [42.3-69.3]
Specificity = 99.7% 99.1-100]
N.B. The above combined test used by APHA from 1st October 2014 comprised the IDEXX ELISA and the Chembio
STAT-PAK lateral flow tests. Replacement of the STAT-PAK with the DPP VetTB lateral flow test by Chembio led to the
exchange of the STAT-PAK in the APHA camelid combined test with the new DPP VetTB test. APHA validation data
showed the DPP VetTB to have similar test specificities when used in the above combined test with the IDEXX ELISA
(Parallel 92.9% [89.6-96.2]; Serial 99.6% [98.7-100]). Preliminary data also suggested that the sensitivity of the DPP
VetTB is equivalent to that of the STAT-PAK.
Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko,
K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and
antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.

Quarterly Camelid Serology Report
07 Oct 2015
Table 1a
Country
No.
Samples
Tested
England
554
Wales
122
Non GB
21
Total for Q3
697
Number of Samples tested and Submission Reason  2015 Q3 (July - September)
Table 1b
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
27
PAR-TB
113
PAR-TRC
32
Parallel
Sum:
172
Serial
SER-COL
31
SER-CONT
195
SER-EPI
242
Serial
Sum:
468
Commercial/Private Testing SER-DIAG
33
SER-MVT
24
Commercial/Private Testing
Sum:
57
Total for Q3
Sum:
697

Quarterly Camelid Serology Report
07 Oct 2015
Table 2a
Country
No.
Samples
Tested
England
986
Wales
285
Non GB
78
Total for Q3
1349
Number of Samples tested and Submission Reason 2015 up to end of Q3 (January - September)
Table 2b
APHA/DEFRA
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
39
PAR-TB
226
PAR-TRC
44
Parallel
Sum:
309
Serial
SER-COL
69
SER-CONT
438
SER-EPI
411
Serial
Sum:
918
Commercial/Private Testing
SER-DIAG
35
SER-MVT
83
SER-RHT
4
Commercial/Private Testing
Sum:
122
Total for 2015 up to end
of Q3
1349

Quarterly Camelid Serology Report
07 Oct 2015
Table 3a
Submissions Received and Test Positivity in 2015 Q3
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
2
27
5
18.5%
PAR-TB
5
113
27
23.9%
PAR-TRC
2
23
9
39.1%
Parallel
9
163
41
25.2%
Serial
SER-COL
4
31
0
0
SER-CONT
13
91
1
1.1%
SER-EPI
3
236
13
5.5%
Serial
20
358
14
3.9%
Commercial/Private Testing
SER-DIAG
5
33
2
6.1%
Commercial/Private Testing
5
33
2
6.1%
England Total
34
554
57
10.3%
Wales
Parallel
PAR-TRC
3
9
1
11.1%
Parallel
3
9
1
11.1%
Serial
SER-CONT
7
104
5
4.8%
SER-EPI
1
6
0
0
Serial
8
110
5
4.5%
Commercial/Private Testing
SER-MVT
1
3
0
0
Commercial/Private Testing
1
3
0
0
Wales Total
12
122
6
4.9%
Non GB
Commercial/Private Testing
SER-MVT
2
21
3
14.3%
Commercial/Private Testing
2
21
3
14.3%
Non GB Total
2
21
3
14.3%
Totals for Q3
48
697
66
9.5 %
Test Positivity in 2015 Q3 (July - September)

Quarterly Camelid Serology Report
07 Oct 2015
Table 3b
Submissions Received and Test Positivity in 2015 up to the end of Q3
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
3
37
6
16.2%
PAR-TB
9
221
67
30.3%
PAR-TRC
5
35
11
31.4%
Parallel
17
293
84
28.7%
Serial
SER-COL
12
69
1
1.4%
SER-CONT
31
178
7
3.9%
SER-EPI
10
405
39
9.6%
Serial
53
652
47
7.2%
Commercial/Private Testing
SER-DIAG
7
35
2
5.7%
SER-MVT
2
2
1
50.0%
SER-RHT
2
4
0
0
Commercial/Private Testing
11
41
3
7.3%
England Total
81
986
134
13.6%
Wales
Parallel
PAR-SUS
1
2
2
100.0%
PAR-TB
1
5
3
60.0%
PAR-TRC
3
9
1
11.1%
Parallel
5
16
6
37.5%
Serial
SER-CONT
17
260
20
7.7%
SER-EPI
1
6
0
0
Serial
18
266
20
7.5%
Commercial/Private Testing
SER-MVT
1
3
0
0
Commercial/Private Testing
1
3
0
0
Wales Total
24
285
26
9.1%
Non GB
Commercial/Private Testing
SER-MVT
9
78
9
11.5%
Commercial/Private Testing
9
78
9
11.5%
Non GB Total
9
78
9
11.5%
Totals up to
end Q3
114
1,349
169
12.5 %
Test Positivity in 2015 up to end of Q3 (January - September)

Quarterly Camelid Serology Report
07 Oct 2015
Submissions Received in 2015 up to end of Q3
Analysis
Analysis Description
Q1
No.
samples
tested
Q2
No.
samples
tested
Q3
No.
samples
tested
Totals up to end Q3
TC0615
Camelid TB DPP VetTB
antibody test
496
496
TC0677
Lateral flow for
Mycobacterium bovis
306
346
201
853
TC0867
Camelid TB Antibody
ELISA
306
346
697
1,349
Table 4: Number of samples Tested by Test Code